1235 related articles for article (PubMed ID: 30503213)
1. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
André P; Denis C; Soulas C; Bourbon-Caillet C; Lopez J; Arnoux T; Bléry M; Bonnafous C; Gauthier L; Morel A; Rossi B; Remark R; Breso V; Bonnet E; Habif G; Guia S; Lalanne AI; Hoffmann C; Lantz O; Fayette J; Boyer-Chammard A; Zerbib R; Dodion P; Ghadially H; Jure-Kunkel M; Morel Y; Herbst R; Narni-Mancinelli E; Cohen RB; Vivier E
Cell; 2018 Dec; 175(7):1731-1743.e13. PubMed ID: 30503213
[TBL] [Abstract][Full Text] [Related]
2. Monalizumab: inhibiting the novel immune checkpoint NKG2A.
van Hall T; André P; Horowitz A; Ruan DF; Borst L; Zerbib R; Narni-Mancinelli E; van der Burg SH; Vivier E
J Immunother Cancer; 2019 Oct; 7(1):263. PubMed ID: 31623687
[TBL] [Abstract][Full Text] [Related]
3. Quantitative modeling predicts competitive advantages of a next generation anti-NKG2A monoclonal antibody over monalizumab for the treatment of cancer.
Spinosa P; Musial-Siwek M; Presler M; Betts A; Rosentrater E; Villali J; Wille L; Zhao Y; McCaughtry T; Subramanian K; Liu H
CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):220-229. PubMed ID: 33501768
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for head and neck cancers: an update and future perspectives.
Doescher J; Laban S; Schuler PJ; Brunner C; Hoffmann TK
Immunotherapy; 2019 May; 11(7):561-564. PubMed ID: 30943860
[No Abstract] [Full Text] [Related]
5. NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.
van Montfoort N; Borst L; Korrer MJ; Sluijter M; Marijt KA; Santegoets SJ; van Ham VJ; Ehsan I; Charoentong P; André P; Wagtmann N; Welters MJP; Kim YJ; Piersma SJ; van der Burg SH; van Hall T
Cell; 2018 Dec; 175(7):1744-1755.e15. PubMed ID: 30503208
[TBL] [Abstract][Full Text] [Related]
6. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
7. Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy.
Zaghi E; Calvi M; Marcenaro E; Mavilio D; Di Vito C
J Leukoc Biol; 2019 Jun; 105(6):1243-1251. PubMed ID: 30645023
[TBL] [Abstract][Full Text] [Related]
8. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines.
Lee J; Keam B; Park HR; Park JE; Kim S; Kim M; Kim TM; Kim DW; Heo DS
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5705-5715. PubMed ID: 36547689
[TBL] [Abstract][Full Text] [Related]
9. Enhancing Natural Killer and CD8
Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
[TBL] [Abstract][Full Text] [Related]
10. CD8
Chen Y; Xin Z; Huang L; Zhao L; Wang S; Cheng J; Wu P; Chai Y
Front Immunol; 2019; 10():3002. PubMed ID: 32010126
[No Abstract] [Full Text] [Related]
11. Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer.
Ducoin K; Oger R; Bilonda Mutala L; Deleine C; Jouand N; Desfrançois J; Podevin J; Duchalais E; Cruard J; Benlalam H; Labarrière N; Bossard C; Jarry A; Gervois-Segain N
Oncoimmunology; 2022; 11(1):2046931. PubMed ID: 35295095
[TBL] [Abstract][Full Text] [Related]
12. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice.
Li F; Wei H; Wei H; Gao Y; Xu L; Yin W; Sun R; Tian Z
Gastroenterology; 2013 Feb; 144(2):392-401. PubMed ID: 23103614
[TBL] [Abstract][Full Text] [Related]
13. The NKG2A-HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment.
Borst L; van der Burg SH; van Hall T
Clin Cancer Res; 2020 Nov; 26(21):5549-5556. PubMed ID: 32409305
[TBL] [Abstract][Full Text] [Related]
14. NKG2A is a NK cell exhaustion checkpoint for HCV persistence.
Zhang C; Wang XM; Li SR; Twelkmeyer T; Wang WH; Zhang SY; Wang SF; Chen JZ; Jin X; Wu YZ; Chen XW; Wang SD; Niu JQ; Chen HR; Tang H
Nat Commun; 2019 Apr; 10(1):1507. PubMed ID: 30944315
[TBL] [Abstract][Full Text] [Related]
15. [New frontiers in the fight against cancer].
Chiossone L; Vivier E
Biol Aujourdhui; 2018; 212(3-4):61-67. PubMed ID: 30973133
[TBL] [Abstract][Full Text] [Related]
16. Restoring NK cells functionality via cytokine activation enhances cetuximab-mediated NK-cell ADCC: A promising therapeutic tool for HCC patients.
Mahgoub S; Abosalem H; Emara M; Kotb N; Maged A; Soror S
Mol Immunol; 2021 Sep; 137():221-227. PubMed ID: 34284214
[TBL] [Abstract][Full Text] [Related]
17. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells.
Kamiya T; Seow SV; Wong D; Robinson M; Campana D
J Clin Invest; 2019 May; 129(5):2094-2106. PubMed ID: 30860984
[TBL] [Abstract][Full Text] [Related]
18. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
[TBL] [Abstract][Full Text] [Related]
19. Increased PD-1
Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
[TBL] [Abstract][Full Text] [Related]
20. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
